ES2089665T3 - Terazosina polimorfa y composicion farmaceutica. - Google Patents

Terazosina polimorfa y composicion farmaceutica.

Info

Publication number
ES2089665T3
ES2089665T3 ES93115607T ES93115607T ES2089665T3 ES 2089665 T3 ES2089665 T3 ES 2089665T3 ES 93115607 T ES93115607 T ES 93115607T ES 93115607 T ES93115607 T ES 93115607T ES 2089665 T3 ES2089665 T3 ES 2089665T3
Authority
ES
Spain
Prior art keywords
terazosin
polymorphic
pharmaceutical composition
new
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93115607T
Other languages
English (en)
Inventor
Glenn A Meyer
John F Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2089665(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2089665T3 publication Critical patent/ES2089665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE UN NUEVO POLIMORFO CRISTALINO ANHIDRIDO DE MONOHIDROCLORURO DE 1 INIL) PO QUE FORMULACIONES FARMACEUTICAS QUE CONTIENEN EL COMPONENTE. EL NUEVO POLIMORFO EXHIBE UN EFECTO DE COMIDA DISMINUIDA CUANDO SE ADMINISTRA A SUJETOS HUMANOS.
ES93115607T 1993-04-29 1993-09-28 Terazosina polimorfa y composicion farmaceutica. Expired - Lifetime ES2089665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5491793A 1993-04-29 1993-04-29
US08/090,721 US5294615A (en) 1993-04-29 1993-07-13 Terazosin polymorph and pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2089665T3 true ES2089665T3 (es) 1996-10-01

Family

ID=26733641

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93115607T Expired - Lifetime ES2089665T3 (es) 1993-04-29 1993-09-28 Terazosina polimorfa y composicion farmaceutica.

Country Status (9)

Country Link
US (2) US5294615A (es)
EP (1) EP0623612B1 (es)
JP (1) JP2755895B2 (es)
DE (1) DE69300913T2 (es)
DK (1) DK0623612T3 (es)
ES (1) ES2089665T3 (es)
GR (1) GR3018433T3 (es)
HK (1) HK124397A (es)
MX (1) MX9306196A (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596109A (en) * 1992-03-24 1997-01-21 Smithkline Beecham Corporation N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid polymorph A
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
IT1286790B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridrato anidro
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
EP0849266B8 (de) * 1996-12-20 2007-10-03 Heumann PCS GmbH Neue polymorphe Form von Doxazosinmesylat (Form III)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
UA72922C2 (uk) * 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
ATE405577T1 (de) * 2000-11-17 2008-09-15 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
TWI353979B (en) 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US7097967B2 (en) * 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
AU2007286186A1 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
CN102321563B (zh) 2011-10-24 2013-04-03 江南大学 一株拟无枝酸菌及利用其全细胞转化制备香草醛的方法
US9096428B2 (en) * 2013-03-08 2015-08-04 Taiwan Semiconductor Manufacturing Company, Ltd. Methods and apparatus for MEMS structure release
US11224572B1 (en) 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
JP2652272B2 (ja) * 1990-12-31 1997-09-10 住化ファインケム株式会社 １−（４−アミノ−６，７−ジメトキシ−２−キナゾリニル）−４−（２−テトラヒドロフロイル）ピペラジン塩酸塩の新規な結晶体および該結晶体の製造方法

Also Published As

Publication number Publication date
EP0623612A1 (en) 1994-11-09
US5294615A (en) 1994-03-15
GR3018433T3 (en) 1996-03-31
DE69300913D1 (de) 1996-01-11
HK124397A (en) 1997-09-12
JP2755895B2 (ja) 1998-05-25
DK0623612T3 (da) 1996-02-05
EP0623612B1 (en) 1995-11-29
DE69300913T2 (de) 1996-05-02
MX9306196A (es) 1994-01-31
US5362730A (en) 1994-11-08
JPH06312984A (ja) 1994-11-08

Similar Documents

Publication Publication Date Title
ES2089665T3 (es) Terazosina polimorfa y composicion farmaceutica.
SE0001899D0 (sv) New compounds
SE8804629D0 (sv) New therapeutically active compounds
SE8700499D0 (sv) Novel pharmacologically active compounds
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
MY100343A (en) Amide derivative and external medicament comprising same
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
YU56995A (sh) Soli derivata indola
CA2000985A1 (en) 1,4-diazepine derivative and its pharmaceutical use
ZA948669B (en) New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
ES2128519T3 (es) Nuevas pirido-tiadiazinas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
HU906284D0 (en) Process for the production of 24-homo-d-vitamin derivatives and medical preparations containing them as active agents
SG46307A1 (en) New pyrazine derivatives the preparation and use thereof
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
NO881616L (no) Middel til innsekts- og middbekjempelse.
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ES2062443T3 (es) Nuevos derivados peptidicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
EA199801028A1 (ru) Применение производных п-аминофенола для проготовления фармацевтических композиций, используемых при лечении нейродегенеративных заболеваний
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
KR910018381A (ko) 개선된 에르골린-8-카복스아미드
FI913034A0 (fi) Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 623612

Country of ref document: ES

FG2A Definitive protection

Ref document number: 623612

Country of ref document: ES